HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
Submission of Matters to a Vote of Security Holders.
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Files An 8-K Submission of Matters to a Vote of Security Holders
On August 15, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the“Annual Meeting”). As of June 16, 2017, the record date for the Annual Meeting, 10,641,456 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.
Proposal 1. Election of Directors
The Company’s stockholders elected the two persons listed below as Class II Directors, each to serve until the Company’s 2020 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:
|
Votes For |
Votes Withheld |
Broker Non-Votes |
|
|
Harry A. George |
3,935,752 |
136,248 |
3,621,712 |
|
Donnie M. Hardison |
4,017,303 |
54,697 |
3,621,712 |
Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2017. The final voting results are as follows:
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|
7,291,473 |
185,935 |
216,304 |
About HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM)
HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.
